KAHR Bio Announces Oral Presentation of Phase 2 Study of DSP107 in Combination with anti-PD-L1 in Colorectal Cancer at 2025 ASCO Annual Meeting

By SquaredTown on May 27, 2025

DSP107 in combination with atezolizumab in 3rd line microsatellite stable colorectal cancer (MSS-CRC) patients elicits anti-tumor activity and extends survival including in patients with liver metastases MODI'IN, Israel, May 27, 2025 /PRNewswire/ -- KAHR, a clinical-stage biotech company...

Read More